Trade Verve Therapeutics, Inc. - VERV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.52 |
| Open | 4.53 |
| 1-Year Change | -63.2% |
| Day's Range | 4.43 - 4.66 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 4.57 | 0.06 | 1.33% | 4.51 | 4.67 | 4.42 |
| Nov 20, 2024 | 4.52 | -0.19 | -4.03% | 4.71 | 4.80 | 4.46 |
| Nov 19, 2024 | 4.82 | 0.34 | 7.59% | 4.48 | 4.90 | 4.48 |
| Nov 18, 2024 | 4.47 | -0.32 | -6.68% | 4.79 | 4.88 | 4.46 |
| Nov 15, 2024 | 4.76 | -0.62 | -11.52% | 5.38 | 5.38 | 4.76 |
| Nov 14, 2024 | 5.37 | -0.33 | -5.79% | 5.70 | 5.81 | 5.37 |
| Nov 13, 2024 | 5.76 | -0.77 | -11.79% | 6.53 | 6.66 | 5.76 |
| Nov 12, 2024 | 6.40 | 0.11 | 1.75% | 6.29 | 6.47 | 6.18 |
| Nov 11, 2024 | 6.40 | 0.06 | 0.95% | 6.34 | 6.72 | 6.24 |
| Nov 8, 2024 | 6.29 | 0.10 | 1.62% | 6.19 | 6.36 | 6.13 |
| Nov 7, 2024 | 6.34 | -0.06 | -0.94% | 6.40 | 6.62 | 6.00 |
| Nov 6, 2024 | 6.39 | -0.07 | -1.08% | 6.46 | 6.78 | 6.26 |
| Nov 5, 2024 | 6.35 | 0.26 | 4.27% | 6.09 | 6.74 | 6.09 |
| Nov 4, 2024 | 6.02 | 0.10 | 1.69% | 5.92 | 6.14 | 5.60 |
| Nov 1, 2024 | 5.88 | 0.16 | 2.80% | 5.72 | 5.93 | 5.63 |
| Oct 31, 2024 | 5.71 | -0.04 | -0.70% | 5.75 | 5.80 | 5.60 |
| Oct 30, 2024 | 5.77 | -0.14 | -2.37% | 5.91 | 6.12 | 5.65 |
| Oct 29, 2024 | 5.97 | 0.09 | 1.53% | 5.88 | 6.16 | 5.83 |
| Oct 28, 2024 | 5.92 | -0.04 | -0.67% | 5.96 | 6.42 | 5.91 |
| Oct 25, 2024 | 5.95 | 0.26 | 4.57% | 5.69 | 6.06 | 5.68 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Verve Therapeutics, Inc. Company profile
About Verve Therapeutics Inc
Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Verve Therapeutics Inc revenues was not reported. Net loss increased from $45.7M to $120.3M. Higher net loss reflects Fair Value of antidilution rights increase from $5.4M to $25.6M (expense), Fair Value Adjustment of success payment increase from $2.4M to $7.8M (expense), Interest Income - Non Bank decrease of 12% to $142K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
201 Brookline Avenue
Suite 601
BOSTON
MASSACHUSETTS 02215
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com